• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

    11/14/24 5:50:33 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYRE alert in real time by email
    SC 13G/A 1 tm2428137d15_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Spyre Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value Per Share

    (Title of Class of Securities)

     

    00773J202

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 00773J202Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3.

    SEC Use Only

     

       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☒ (1)      (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,685,448 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,685,448 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,685,448 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

     

    CUSIP No. 00773J202Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Spyre Therapeutics, Inc.

     

    Item 1.    
      (a)

    Name of Issuer

     

    Spyre Therapeutics, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    221 Crescent Street

    Building 23, Suite 105

    Waltham, MA 02453

         
    Item 2.    
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

         
      (b)

    Address of Principal Business Office or, if none, Residence

           
        New York Office: Palo Alto Office:
           
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018  
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

         
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value per share

         
      (e)

    CUSIP Number

     

    00773J202

     

     

    CUSIP No. 00773J202Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    Item 4. Ownership  

     

      (a) Amount beneficially owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   2,685,448(1)
    VHCP Co-Investment Holdings III, LLC   2,685,448(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,685,448(1)
    VHCP Management III, LLC   2,685,448(1)
    VHCP Management EG, LLC   2,685,448(1)
    Nimish Shah   2,685,448(1)
    Bong Koh   2,685,448(1)

     

      (b) Percent of class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   5.3%(2)
    VHCP Co-Investment Holdings III, LLC   5.3%(2)
    Venrock Healthcare Capital Partners EG, L.P.   5.3%(2)
    VHCP Management III, LLC   5.3%(2)
    VHCP Management EG, LLC   5.3%(2)
    Nimish Shah   5.3%(2)
    Bong Koh   5.3%(2)

     

      (c) Number of shares as to which the person has, as of September 30, 2024:
         
        (i) Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

    CUSIP No. 00773J202Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   2,685,448(1)
    VHCP Co-Investment Holdings III, LLC   2,685,448(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,685,448(1)
    VHCP Management III, LLC   2,685,448(1)
    VHCP Management EG, LLC   2,685,448(1)
    Nimish Shah   2,685,448(1)
    Bong Koh   2,685,448(1)

     

        (iii) Sole power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   2,685,448(1)
    VHCP Co-Investment Holdings III, LLC   2,685,448(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,685,448(1)
    VHCP Management III, LLC   2,685,448(1)
    VHCP Management EG, LLC   2,685,448(1)
    Nimish Shah   2,685,448(1)
    Bong Koh   2,685,448(1)

     

     (1)Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.
       
     VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
       
     (2)This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐

     

     

    CUSIP No. 00773J202Page 12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

    CUSIP No. 00773J202Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
             
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    VHCP Co-Investment Holdings III, LLC      
             
    By: VHCP Management III, LLC      
    Its: Manager      
             
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther      
      Its: Authorized Signatory      
             
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    Nimish Shah      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      
             
    Bong Koh      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      

     

     

    CUSIP No. 00773J202Page 14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on July 10, 2023)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed July 10, 2023)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on July 10, 2023)

     

     

     

    Get the next $SYRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYRE

    DatePrice TargetRatingAnalyst
    4/8/2025$45.00Outperform
    Leerink Partners
    3/18/2025$27.00Outperform
    Wolfe Research
    9/4/2024$45.00Outperform
    Wedbush
    7/16/2024Outperform
    Evercore ISI
    5/2/2024$50.00Outperform
    Robert W. Baird
    3/1/2024$12.00 → $35.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $SYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      11/14/24 5:50:33 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      11/14/24 4:33:26 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      11/14/24 4:05:09 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRE
    Financials

    Live finance-specific insights

    See more
    • Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

      SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 (longest follow-up available for pharmacodynamic data) Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, follow

      11/12/24 7:30:00 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

      WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre

      11/11/24 4:05:00 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spyre Therapeutics Announces Grants of Inducement Awards

      WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock o

      6/6/25 4:05:00 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics to Participate in Upcoming June Investor Conferences

      WALTHAM, Mass., May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Fireside Time: 8:10am ET Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025Date: Monday, June 9, 2025Fireside Time: 9:20am ET Live audio webcasts and replays of these

      5/28/25 8:30:00 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or biannual dosing, and provides complete target engagement at expected Phase 2 trough concentrations Remain on track to report interim Phase 1 data for SPY002 later this quarter, with the potential to demonstrate a product profile superior to first-generation TL1A antibodies Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and sa

      5/8/25 4:05:00 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Spyre Therapeutics with a new price target

      Leerink Partners initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00

      4/8/25 9:31:30 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Spyre Therapeutics with a new price target

      Wolfe Research initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $27.00

      3/18/25 7:56:48 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Spyre Therapeutics with a new price target

      Wedbush initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00

      9/4/24 8:21:08 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab  Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini

      11/7/24 4:05:00 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

      WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years

      10/1/24 8:00:00 AM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities

      8/7/24 4:05:00 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRE
    SEC Filings

    See more
    • Spyre Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

      6/2/25 4:02:10 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

      5/8/25 4:05:36 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Spyre Therapeutics Inc.

      10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)

      5/8/25 4:01:12 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fairmount Funds Management Llc

      4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      6/2/25 4:39:53 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stelzer Laurie

      4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      6/2/25 4:38:36 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Milligan Sandra

      4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      6/2/25 4:37:14 PM ET
      $SYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care